The Potential Use of Antibiotics Against Helicobacter Pylori Infection: Biopharmaceutical Implications

The Potential Use of Antibiotics Against Helicobacter Pylori Infection: Biopharmaceutical Implications Publisher

Miri AH^{1, 2} ; Kamankesh M³ ; Llopislorente A⁴ ; Liu C⁵ ; Wacker MG⁶ ; Haririan I¹ ; Asadzadeh Aghdaei H⁷ ; Hamblin MR⁸ ; Yadegar A² ; Radmalekshahi M¹ ; Zali MR⁹

Show Affiliations

1. Department of Pharmaceutical Biomaterials and Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
2. Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Polymer Chemistry Department, School of Science, University of Tehran, Tehran, Iran
4. Institute for Complex Molecular Systems, Eindhoven University of Technology, Eindhoven, Netherlands
5. College of Marine Life Science, Ocean University of China, Qingdao, China
6. Department of Pharmacy, National University of Singapore, Singapore, Singapore
7. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
8. Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, South Africa
9. Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Frontiers in Pharmacology Published:2022

Abstract

Helicobacter pylori (H. pylori) is a notorious, recalcitrant and silent germ, which can cause a variety of debilitating stomach diseases, including gastric and duodenal ulcers and gastric cancer. This microbe predominantly colonizes the mucosal layer of the human stomach and survives in the inhospitable gastric microenvironment, by adapting to this hostile milieu. In this review, we first discuss H. pylori colonization and invasion. Thereafter, we provide a survey of current curative options based on polypharmacy, looking at pharmacokinetics, pharmacodynamics and pharmaceutical microbiology concepts, in the battle against H. pylori infection. Copyright © 2022 Miri, Kamankesh, Llopis-Lorente, Liu, Wacker, Haririan, Asadzadeh Aghdaei, Hamblin, Yadegar, Rad-Malekshahi and Zali.

Related Docs

View other Related Docs

1. Factors Associated With Treatment Failure, and Possible Applications of Probiotic Bacteria in the Arsenal Against Helicobacter Pylori, Expert Review of Anti-Infective Therapy (2023)

2. Expression Assessment of the Helicobacter Pylori Baba and Saba Genes in Patients With Peptic Ulcer, Duodenal Ulcer and Gastric Cancer, International Journal of Molecular and Cellular Medicine (2023)

3. Helicobacter Pylori Infection: Conventional and Molecular Strategies for Bacterial Diagnosis and Antibiotic Resistance Testing, Current Pharmaceutical Biotechnology (2023)

4. In Vitro Evaluation of Cross-Strain Inhibitory Effects of Igy Polyclonal Antibody Against H. Pylori, Microbial Pathogenesis (2017)

5. Antibiotic Resistance of Helicobacter Pylori Infection and Its Eradication Rate in Different Regions of Iran; a Review, Govaresh (2020)

6. Molecular Mechanisms Underlying the Action of Carcinogens in Gastric Cancer With a Glimpse Into Targeted Therapy, Cellular Oncology (2022)

7. Worldwide and Regional Efficacy Estimates of First-Line Helicobacter Pylori Treatments: A Systematic Review and Network Meta-Analysis, Journal of Clinical Gastroenterology (2022)

8. Association of Helicobacter Pylori Infection With the Risk of Metabolic Syndrome and Insulin Resistance: An Updated Systematic Review and Meta-Analysis, Diabetology and Metabolic Syndrome (2021)

Experts (# of related papers)

View all Related Experts

Reza Malekzadeh (1)

Alimohammad Alizadeh (1)

Style	Citing Format
MLA	Miri AH, et al.. "The Potential Use of Antibiotics Against Helicobacter Pylori Infection: Biopharmaceutical Implications." Frontiers in Pharmacology, vol. 13, no. , 2022, pp. -.
APA	Miri AH, Kamankesh M, Llopislorente A, Liu C, Wacker MG, Haririan I, Asadzadeh Aghdaei H, Hamblin MR, Yadegar A, Radmalekshahi M, Zali MR (2022). The Potential Use of Antibiotics Against Helicobacter Pylori Infection: Biopharmaceutical Implications. Frontiers in Pharmacology, 13(), -.
Chicago	Miri AH, Kamankesh M, Llopislorente A, Liu C, Wacker MG, Haririan I, Asadzadeh Aghdaei H, et al.. "The Potential Use of Antibiotics Against Helicobacter Pylori Infection: Biopharmaceutical Implications." Frontiers in Pharmacology 13, no. (2022): -.
Harvard	Miri AH et al. (2022) 'The Potential Use of Antibiotics Against Helicobacter Pylori Infection: Biopharmaceutical Implications', Frontiers in Pharmacology, 13(), pp. -.
Vancouver	Miri AH, Kamankesh M, Llopislorente A, Liu C, Wacker MG, Haririan I, et al.. The Potential Use of Antibiotics Against Helicobacter Pylori Infection: Biopharmaceutical Implications. Frontiers in Pharmacology. 2022;13():-.
BibTex	@article{ author = {Miri AH and Kamankesh M and Llopislorente A and Liu C and Wacker MG and Haririan I and Asadzadeh Aghdaei H and Hamblin MR and Yadegar A and Radmalekshahi M and Zali MR}, title = {The Potential Use of Antibiotics Against Helicobacter Pylori Infection: Biopharmaceutical Implications}, journal = {Frontiers in Pharmacology}, volume = {13}, number = {}, pages = {-}, year = {2022} }
RIS	TY - JOUR AU - Miri AH AU - Kamankesh M AU - Llopislorente A AU - Liu C AU - Wacker MG AU - Haririan I AU - Asadzadeh Aghdaei H AU - Hamblin MR AU - Yadegar A AU - Radmalekshahi M AU - Zali MR TI - The Potential Use of Antibiotics Against Helicobacter Pylori Infection: Biopharmaceutical Implications JO - Frontiers in Pharmacology VL - 13 IS - SP - EP - PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract